Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 24, 1998

View Archived Issues

Procyon receives Japanese patent for prostate cancer treatment

PowderJect delivery of DNA vaccines validated in preclinical study

Expanded approval requested for chemoprotective agent

Myriad Genetics: Q4 and FY 1998 highlights

More on NPY receptor antagonists developed at Banyu

Mitsui Chemicals prepares cell adhesion inhibitors

Hydroxamic acids as cancer cell differentiation inducers under study at Mitsui Chemicals

Another series of DC-107 derivatives from Kyowa Hakko particularly useful as antitumor agents

Belgian academic researchers prepare bioisosteres of BM-34 as new anticonvulsants

OraPharma begins collaboration with U.N.C. for dental and related diseases

Isis Pharmaceuticals receives milestone payment from Ciba Vision for Vitravene

New paclitaxel formulation enters clinical trials

TheraTech receives NIH funding for novel approach to rheumatoid arthritis

Cangene signs WinRho distribution agreement for Australia

Biomira and Biovector collaborate on development of idiotypic B-cell lymphoma vaccine

Tranzyme obtains technology license from U. of Alabama

Enzon's PEG-Intron A advances to phase III trials for malignant melanoma

Phase III trials initiated for desloratadine

Pierre Fabre obtains good results with RSV subunit vaccine in monkey model

HemispheRx broadens hepatitis C portfolio

Meiji Seika profiles preclinical activity of new parenteral cephalosporin

Caelyx receives approval in Canada

Safety studies support pediatric use of MKC-442

Independent investigators report efficacy of Eisai cephalosporin

Postmarketing study of Vaqta supports safety of hepatitis A vaccine

Lobucavir is safe and effective in controlling herpes recurrences

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...